| Literature DB >> 28779712 |
Reza Shafiee-Nick1, Amir R Afshari1, Seyed Hadi Mousavi2, Abbasali Rafighdoust3, Vahid Reza Askari4, Hamid Mollazadeh5, Sahar Fanoudi4, Elmira Mohtashami6, Vafa Baradaran Rahimi4, Moein Mohebbi7, Mohammad Mahdi Vahedi8.
Abstract
Phosphodiesterases are a group of enzymes that hydrolyze cyclic nucleotides, which assume a key role in directing intracellular levels of the second messengers' cAMP and cGMP, and consequently cell function. The disclosure of 11 isoenzyme families and our expanded knowledge of their functions at the cell and molecular level stimulate the improvement of isoenzyme selective inhibitors for the treatment of various diseases, particularly cardiovascular diseases. Hence, future and new mechanistic investigations and carefully designed clinical trials could help reap additional benefits of natural/synthetic PDE inhibitors for cardiovascular disease in patients. This review has concentrated on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases.Entities:
Keywords: Cardiovascular disease; Phosphodiesterase; Phosphodiesterase inhibitors; Potential therapeutic
Mesh：
Substances：
Year: 2017 PMID： 28779712 DOI： 10.1016/j.biopha.2017.07.084
Source DB: PubMed Journal: Biomed Pharmacother ISSN： 0753-3322 Impact factor: 6.529